Is the Healthcare AI Market growing now?
In our healthcare AI market deck, you will find everything you need to understand the market
SUMMARY
Yes. The Healthcare AI market is clearly growing now, with spending, adoption, revenue and regulated deployment all moving higher at the same time.
The strongest growth is not coming from autonomous medicine. It is coming from AI that fits into work hospitals already pay people to do: documentation, billing, search, imaging, prior authorization and other operational workflows.
Physician adoption has moved unusually fast. The AMA now finds professional AI use among 81% of surveyed physicians, while the average doctor reports 2.3 AI use cases, suggesting that adoption is deepening inside workflows rather than simply spreading to more users.
Funding is rising, but the market is becoming more concentrated. Digital-health deal count was almost flat in the first half of 2026 while invested capital increased, and very large Healthcare AI rounds absorbed a disproportionate share of the money.
Ambient documentation has become the clearest early mass market because the return is easy to understand. Hospitals can measure time saved on notes quickly, deploy the software inside an existing workflow, and expand it without redesigning clinical care.
Revenue is now appearing across very different business models. Tempus, DeepHealth and OpenEvidence show that Healthcare AI can monetize through precision medicine, recurring imaging software and physician information products rather than through one standard software model.
Clinical AI is growing too, but the pace is slower and more regulated. The FDA authorization record is expanding quickly, with radiology still dominant, which shows both the commercial progress and the limits of where clinical AI is easiest to deploy today.
Patients are becoming a large AI-for-health user group before hospitals or insurers necessarily touch the interaction. That expands the market, but it also means general-purpose platforms such as ChatGPT may capture a meaningful share of consumer health demand that might otherwise have gone to dedicated healthcare startups.
Epic, Microsoft and OpenAI are likely to make the overall market larger while making generic Healthcare AI startups less valuable. Distribution, proprietary data, regulatory clearance, workflow depth and customer trust are becoming much more important than access to a strong model.
The market is therefore growing and maturing at the same time. More money, users, deployments, revenue, approvals and acquisitions are appearing, but the value is concentrating around products that solve expensive existing problems and companies with defensible positions inside healthcare workflows.
This market map, featured in our healthcare AI market deck, highlights top companies and startups in the healthcare AI market
Is the Healthcare AI Market Growing Now?
What would prove that the Healthcare AI market is actually growing?
The Healthcare AI market is genuinely growing today because spending, adoption, revenue and regulated deployment are all moving up at the same time.
A forecast saying the market will be worth $100 billion or $500 billion tells us very little. The definition changes from one research firm to another, especially when some include AI drug discovery, medical devices, hospital software, consumer health apps and analytics in the same number.
We get a cleaner answer by watching what healthcare buyers and users are actually doing. Hospitals need to move AI into production. Doctors need to use it repeatedly. AI vendors need to turn that usage into revenue. Investors need to keep financing the sector. Clinical products need to make it through regulatory review. Acquirers also need to see enough value to buy these companies.
For this article, we focus mainly on AI used by providers, clinicians, payers and patients for clinical workflows, documentation, healthcare data, imaging, diagnostics, decision support and health information. We keep pure AI drug discovery mostly outside the analysis because its economics look much more like biotech: billions can be invested years before a product creates healthcare revenue.
Across those measures, the direction is already clear. Healthcare AI is growing.
Why does Healthcare AI feel different now?
Healthcare AI feels different now because doctors and hospitals are already using it at scale, while the products are spreading from note-taking into search, orders, billing, nursing and clinical support.
The physician numbers have moved very quickly. In the American Medical Association's 2026 survey, 81% of physicians said they were using AI professionally. That compares with 66% in the previous survey and 38% in 2023. The average physician now reports 2.3 AI use cases, up from 1.1 three years earlier.
Hospitals are following the same direction. A national study published in JAMA Network Open found that 31.5% of U.S. hospitals were already using generative AI integrated with their electronic health record in 2024, while another 24.7% planned to introduce it within a year. Generative AI had reached hospital systems surprisingly quickly considering ChatGPT had appeared only two years earlier.
The products are also getting broader. Epic first rolled out built-in AI Charting for physicians and has recently extended ambient documentation into nursing workflows. Abridge has expanded from medical notes toward billing, payer workflows, clinical evidence and decision support. Microsoft is doing the same with Dragon Copilot.
We are increasingly looking at software sitting inside daily healthcare workflows rather than experimental AI tools sitting beside them.
As this chart shows, and as featured in our healthcare AI market deck, search interest in healthcare AI has grown rapidly
Is Healthcare AI funding really going up now?
Yes, Healthcare AI funding is rising now even while healthcare venture capital overall remains much tighter than it was during the 2021 boom.
Silicon Valley Bank calculated that almost $18 billion went into U.S. and European Healthcare AI companies in 2025. AI accounted for 46% of all healthcare investment in its dataset. Overall healthcare investment, meanwhile, fell 12% to $46.8 billion.
The comparison is unusually clean. Healthcare AI did not simply rise because investors were throwing more money at every healthcare category. AI gained a much larger share of a shrinking pool.
The trend had already been forming. SVB's earlier work found that Healthcare AI deal activity had grown much faster than non-AI healthcare activity over several years. By the first half of 2025, Healthtech AI alone represented 21% of healthcare investment, and AI was taking roughly half of the money flowing into diagnostics and tools companies.
The broader digital-health market has strengthened lately too. Rock Health's mid-year analysis found that U.S. digital-health startups raised $7.4 billion across 244 deals in the first half of 2026, up from $6.4 billion across 245 deals one year earlier. Funding rose by roughly 16% with virtually no increase in the number of financings.
The scale still sits far below 2021, when digital-health investment reached extraordinary levels. Today's growth looks more selective and much more centered on companies investors believe can turn AI into an actual healthcare business.
Are investors funding more Healthcare AI companies, or just writing bigger checks?
Investors are mostly writing bigger checks to a narrower group of Healthcare AI winners, so the market is growing with far more concentration than the headline totals suggest.
Rock Health's latest numbers make this easy to see. U.S. digital-health deal count barely moved between the first half of 2025 and the first half of 2026, slipping from 245 deals to 244. Yet invested capital jumped by $1 billion and the median deal size rose from $12 million to $14 million.
Twenty rounds worth at least $100 million absorbed 45% of all digital-health funding during the first half of 2026. Those mega-rounds represented only a little over 8% of financings. In 2024, mega-rounds had taken 22% of total capital. Their share has effectively doubled.
Healthcare AI shows an even stronger version of the same pattern. SVB found more Healthcare AI rounds above $300 million in 2025 than in any previous year it had measured, including 2021. Those very large rounds absorbed about 40% of all Healthcare AI investment.
Abridge is a good example. It reached a $5.3 billion valuation after its 2025 financing and subsequently added hundreds of millions of dollars of further capital. OpenEvidence went from a $3.5 billion valuation in mid-2025 to $6 billion later that year and then $12 billion in early 2026.
For founders, this is a much harsher market than the funding headline suggests. Investors are paying aggressively for perceived category leaders while becoming much less impressed by a startup whose main pitch is simply that it uses a good AI model.
| Funding measure | Earlier period | Latest comparable period | Change |
|---|---|---|---|
| U.S. digital-health funding, first half | $6.4B | $7.4B | +16% |
| U.S. digital-health deals, first half | 245 | 244 | Essentially flat |
| Median digital-health round | $12M | $14M | +17% |
| Share of capital in $100M+ rounds | 22% in 2024 | 45% in H1 2026 | More than doubled |
| Healthcare AI capital in $300M+ rounds | — | ~40% in 2025 | Heavy concentration |
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, shows annual VC investment in healthcare AI startups
Are hospitals actually buying Healthcare AI now?
Yes, U.S. hospitals are buying and rolling out Healthcare AI at a scale that has pushed several products well beyond pilot territory.
Ambient documentation gives us the cleanest evidence. Researchers from Emory examined 2,784 U.S. hospitals using Epic and found that 62.6% had adopted or were implementing an ambient AI documentation product by mid-2025. DAX Copilot, Abridge and ThinkAndor accounted for more than 80% of implementations.
That sample covers only hospitals using Epic, so we should avoid turning the 62.6% figure into a national hospital adoption rate. The result is still striking because those 2,784 hospitals represented more than 40% of U.S. hospitals in the study.
Microsoft gives us another view of scale. The company said earlier this year that more than 100,000 clinicians were already relying on Dragon Copilot in daily practice, supporting care for millions of patients each month. Intermountain Health alone had grown to more than 2,500 active users. Brown Health recently reported more than 400 clinicians using Dragon Copilot alongside more than two dozen internally built AI agents.
Deployment is also broadening across job types. Epic has recently brought its ambient charting technology to nurses at Mount Sinai Medical Center in Florida. Documentation AI initially spread mainly through physician workflows, so this is a meaningful extension.
Healthcare AI purchasing today is concentrated enough to produce identifiable category leaders, but widespread enough that hospital adoption can no longer be explained by a few famous academic medical centers testing new software.
Are doctors actually using Healthcare AI in everyday work?
Yes, Healthcare AI has become part of everyday work for most physicians surveyed by the AMA, with the fastest adoption happening in research, documentation and administrative tasks.
The AMA's latest survey puts professional AI use at 81% of physicians. Three years earlier, the figure was 38%. That is a gain of 43 percentage points in a period when many Healthcare AI products were still being built.
How physicians use the technology tells us even more. Thirty-nine percent now use AI to summarize medical research and standards of care. Thirty percent use it for discharge instructions, care plans or progress notes. Twenty-eight percent use AI for billing codes, medical charts or visit notes, while another 28% use it for chart summaries. Nineteen percent use AI to draft patient portal responses.
Assistive diagnosis sits much lower at 17%.
That gap says a lot. Healthcare AI has grown fastest where a doctor can check the output quickly and where a mistake usually carries less risk. Summarizing evidence or drafting a note has a much easier path into daily use than letting software make a consequential diagnosis by itself.
The average number of AI use cases per physician has also risen from 1.1 in 2023 to 2.3 today. Adoption is broadening inside individual workflows as well as spreading to more doctors.
This chart, featured in our healthcare AI market deck, looks at Tempus AI’s strategy in healthcare AI
Where is Healthcare AI money going first?
The easiest money in Healthcare AI is currently flowing into products that remove expensive administrative work from doctors and health systems.
Silicon Valley Bank found that provider operations captured 44% of Healthtech investment in its 2025 sector analysis. That category covers areas such as scheduling, documentation and billing. About $5.5 billion had already gone into provider operations when SVB published the report, putting the category on pace to exceed its previous funding record.
Ambient AI sits at the center of that boom. Its appeal is easy to understand. Every physician creates documentation, hospitals already know how much time doctors spend in the EHR, and the software can often be added directly to an existing workflow. A buyer can measure minutes saved per encounter within weeks.
Abridge shows how quickly this category is becoming broader. The company started with ambient documentation and now wants the clinical conversation to feed billing, prior authorization, evidence retrieval and clinical decision support. NVIDIA is working with Abridge on a foundation model specifically designed for clinical conversations, while Eli Lilly has also invested strategically in the company.
Revenue-cycle AI is growing beside it. R1 recently agreed to acquire Humata Health, whose software automates prior authorization. Epic is also pushing deeper into authorization workflows and has recently introduced real-time checks that tell clinicians whether an insurer requires authorization before treatment.
The first large Healthcare AI market has formed around removing friction from work hospitals already pay people to do. That is a much easier sale than asking a health system to redesign medicine around a completely new AI workflow.
If you want more recent data on this point, please see our latest healthcare AI market report.
Is clinical Healthcare AI growing too, or is the boom mostly administrative?
Clinical Healthcare AI is growing too, especially in imaging and diagnostics, although it is moving more slowly than administrative AI.
The FDA record makes that clear. A new longitudinal analysis of the FDA's AI-enabled device registry counted 1,430 authorized AI or machine-learning medical devices through the end of 2025, produced by 576 manufacturers across 17 specialties.
The pace is accelerating. The study found an average of only two authorizations per year between 1995 and 2015. From 2023 through 2025, the average reached 264 per year, including 331 authorizations in 2025 alone.
Radiology still dominates. That makes sense because imaging gives AI a relatively standardized input, huge training datasets and a clear way to compare algorithm output with clinical ground truth. Companies can also build AI directly into workflows radiologists already use.
The commercial numbers are beginning to catch up. RadNet's DeepHealth reported $32.4 million of Digital Health revenue in its latest quarter, up 56.5% year over year. Annual recurring revenue reached $105.5 million, almost twice its level one year earlier, and 63% of Digital Health revenue now comes from external customers rather than RadNet's own imaging centers.
Clinical AI already supports real businesses. The route is simply slower because a product influencing diagnosis has to clear a much higher bar for evidence, regulation and trust than a product preparing a medical note.
This chart, featured in our healthcare AI market deck, shows annual funding in healthcare AI startups
Are Healthcare AI companies making real revenue yet?
Yes, several AI-enabled healthcare businesses are already generating revenue at a scale large enough to prove that Healthcare AI has moved beyond venture-funded experimentation.
Tempus AI gives us the best public-company example. Its latest quarterly revenue reached $382.5 million, up 22% year over year. Data and Applications revenue rose 28% to $93.2 million, while its higher-value Insights business grew 36%. Tempus also signed roughly $200 million of new Data and Applications licenses during the quarter.
DeepHealth is much smaller but cleaner as a software growth example. Its quarterly Digital Health revenue increased 56.5% year over year, while annual recurring revenue rose 97.2% to $105.5 million.
OpenEvidence gives us a third model. The physician search and clinical-answer product is free for doctors and monetizes largely through advertising. The Information reported in July 2026 that OpenEvidence was generating roughly $300 million of annualized revenue, around $25 million per month, roughly double the level reported seven months earlier. The company says more than 860,000 licensed U.S. clinicians use the platform.
These businesses should not be added together and called “Healthcare AI revenue.” Tempus includes diagnostic testing, DeepHealth mixes AI with enterprise imaging, and OpenEvidence runs a very different advertising-led model.
The variety is the point. AI is already supporting meaningful revenue in precision medicine, imaging software and physician information products through three completely different business models.
| Company | Latest commercial figure | Growth evidence | What we learn |
|---|---|---|---|
| Tempus AI | $382.5M quarterly revenue | +22% YoY; Data & Applications +28% | AI-enabled precision medicine can support billion-dollar annual revenue |
| DeepHealth | $32.4M quarterly Digital Health revenue; $105.5M ARR | Revenue +56.5%; ARR +97.2% | Imaging AI is becoming a meaningful recurring software business |
| OpenEvidence | Reported ~$300M annualized revenue | Roughly doubled in about seven months | Physician-facing generative AI can monetize very large usage |
Does Healthcare AI actually save hospitals time or money?
Healthcare AI already shows convincing time savings in documentation, while the economic proof is still much thinner across many other healthcare use cases.
Intermountain Health gives us one of the better production datasets. The health system looked at Epic usage data from 2,285 clinicians who had used Dragon Copilot for at least ten encounters. When those clinicians used the product, time spent on notes per appointment fell by 27%.
That does not mean each doctor suddenly became 27% more productive. Documentation is only one part of a clinical day. Still, a reduction of that size in one of the most disliked parts of a physician's workload can justify real spending.
Research from other systems points in the same direction. Studies of ambient documentation have found reductions in after-hours work and documentation burden, while some health systems have reported better physician satisfaction after deployment. Brown Health says its deployment reduced documentation burden for more than 400 clinicians.
The strongest ROI case today is practical and fairly narrow: AI can give clinicians back time that would otherwise be spent typing, searching or rewriting information.
We have much less confidence when vendors claim that AI will transform hospital economics across the board. Products aimed at diagnosis, patient engagement, population health or clinical prediction usually need longer studies before we know whether they consistently lower costs or improve outcomes enough to justify the price.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, compares the main business model options for ambient AI companies
Are patients becoming a real Healthcare AI market too?
Yes, patients are becoming a major Healthcare AI user group, and much of that adoption is happening before hospitals or insurers have any involvement.
Rock Health's consumer survey found that 32% of U.S. adults had used an AI chatbot for health information, twice the 16% reported one year earlier. Among those users, 64% were asking health questions at least weekly.
KFF's more recent tracking adds another useful trajectory. Twenty-nine percent of U.S. adults now say they use AI tools or chatbots for health information at least monthly, up from roughly 17% two years earlier. KFF also found that quick access is the biggest attraction, while some people turn to AI because seeing a healthcare professional is expensive or difficult.
General AI platforms currently capture a huge share of this behavior. In Rock Health's survey, 23% of all respondents had used ChatGPT for health, compared with 5% who had used a provider chatbot and 4% who had used an insurer chatbot.
OpenAI's own global usage data show the scale this can reach. The company says more than 230 million people now use ChatGPT for health and wellness questions in a typical week. Its dedicated Health experience has since begun rolling out in the United States with support for connected medical records and health data.
For dedicated Healthcare AI companies, that creates both an opportunity and a problem. Consumer demand is clearly growing, while much of the traffic may be captured by general-purpose AI companies rather than healthcare startups. Health-related AI usage and Healthcare AI startup revenue will therefore grow at different speeds.
Will Epic, Microsoft and OpenAI make Healthcare AI startups less valuable?
Epic, Microsoft and OpenAI will make generic Healthcare AI startups less valuable, even as their distribution makes the overall Healthcare AI market much bigger.
Epic is already building AI directly into the electronic health record. AI Charting can listen to a patient visit, draft documentation and prepare orders. Epic has since pushed the technology into nursing and broader visit workflows. A hospital already running Epic now has a growing menu of AI functions available inside its core system.
Microsoft enters with another major advantage: existing healthcare distribution. Dragon Copilot already reaches more than 100,000 clinicians, and Microsoft can combine clinical documentation with Azure, security, enterprise identity and a large ecosystem of healthcare partners.
OpenAI has attacked both the consumer and enterprise sides. ChatGPT for Healthcare is already being rolled out at organizations including AdventHealth, Baylor Scott & White Health, Boston Children's Hospital, Cedars-Sinai, HCA Healthcare, Memorial Sloan Kettering, Stanford Medicine Children's Health and UCSF. At the same time, Health in ChatGPT gives OpenAI a direct consumer healthcare product.
Startups can still win, and Abridge is proof. The company says it works with more than 150 health systems and has expanded far beyond basic transcription. OpenEvidence has also become one of the most widely used physician-facing AI products despite competing with general models.
The moat has simply moved. Access to a powerful model is becoming ordinary. Healthcare startups increasingly need something harder to copy: distribution, proprietary clinical data, deep workflow integration, regulatory clearance, trusted medical content or an unusually strong position with a specific customer group.
That should make the mature Healthcare AI market more valuable and more brutal at the same time.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, illustrates how revenue is distributed across customer segments in the healthcare AI market
Is regulation slowing Healthcare AI down?
Regulation is slowing high-risk clinical Healthcare AI more than workflow AI, and the current FDA picture looks more like a filter than a wall.
The 1,430 AI-enabled medical devices authorized through 2025 show that regulated AI can reach the U.S. market at meaningful scale. The FDA continues to add new AI-enabled devices, with radiology still representing the largest group.
Generative AI creates a harder regulatory problem. A conventional imaging algorithm can often be tested against a fixed task. A generative model can produce different language from one interaction to the next, change through model updates and take on broader tasks over time.
The FDA has just opened a new public discussion around how generative-AI-enabled medical devices should be evaluated before launch and monitored afterward. The questions include risk assessment, premarket evidence, model changes and post-market monitoring.
Physicians are asking for the same caution. The AMA's latest work shows that enthusiasm for AI has risen strongly, but doctors continue to put heavy weight on safety, privacy and professional oversight.
This creates a very uneven market. AI that drafts a note can spread quickly because a clinician reviews the output before it enters the record. AI that directly changes a diagnosis or treatment decision has a much longer road.
For companies that make it through that road, regulation can become an advantage. Clinical evidence, approvals and hospital trust are all expensive to reproduce, which gives validated vendors protection from the flood of generic AI applications entering healthcare.
Is Healthcare AI already consolidating?
Yes, Healthcare AI is already moving into consolidation, with recent acquisitions showing larger healthcare companies buying AI capabilities rather than building every workflow themselves.
The broader digital-health deal market has become particularly active. Rock Health counted 115 U.S. digital-health acquisitions in the first half of 2026, and the second quarter was the busiest acquisition quarter since 2021.
AI is increasingly visible inside those deals. R1 recently agreed to acquire Humata Health to add AI-powered prior authorization automation to its revenue-cycle platform. RadNet bought radiology-AI company Gleamer, which had built more than 700 customer contracts. Tempus has agreed to acquire Personalis at an enterprise value of roughly $1.5 billion, adding molecular residual disease technology and data to its precision-medicine platform.
These transactions differ greatly in size and business model, so we should not read them as one clean Healthcare AI M&A dataset. The pattern is still clear: companies with healthcare distribution are buying specialized technology, customer contracts and datasets that can be plugged into a wider platform.
That pattern should become more common as AI features get easier to build. A large healthcare company has less reason to acquire a startup simply for its language model. A startup with 700 hospital customers, unique clinical data, regulatory approvals or a deeply embedded workflow gives the buyer something much harder to recreate.
Consolidation looks compatible with continued market growth. In fact, it may be one of the clearest signs that Healthcare AI is maturing.
This chart, featured in our healthcare AI market deck, shows how symptom checker app technology has evolved over time
So, is the Healthcare AI market growing now?
Yes. The Healthcare AI market is clearly growing now, and the strongest evidence comes from what doctors, hospitals and customers are already doing rather than from market-size forecasts.
Capital has moved sharply toward AI even during a difficult healthcare funding environment. Healthcare AI took 46% of healthcare investment in SVB's 2025 analysis. Digital-health funding has since risen again, although that money is concentrating heavily in large rounds and perceived category winners.
Actual usage is harder to dismiss. As seen above, the AMA now finds AI in the professional workflows of more than four in five surveyed physicians. Hospital studies show generative AI and ambient documentation spreading through large parts of the U.S. health system. Consumer use has also risen quickly enough that roughly three in ten U.S. adults now use AI for health information at least monthly.
Revenue has started to catch up with adoption. Tempus is operating at more than a billion dollars of annual revenue, DeepHealth has nearly doubled recurring Digital Health revenue in a year, and OpenEvidence has reportedly reached hundreds of millions of dollars in annualized revenue. Regulated clinical AI is growing at the same time, with hundreds of new FDA authorizations appearing each year.
The important qualification is where the growth sits. Healthcare AI currently works best as a market when the customer already has an expensive problem and the AI fits into an existing workflow. Documentation, provider operations, imaging, healthcare data and medical information search all meet that test. More autonomous clinical applications remain much harder.
We judge the claim as true, with high confidence: Healthcare AI is a growing market today.
The opportunity is becoming more concentrated, though. A few companies are absorbing huge funding rounds, Epic and Microsoft are bundling AI into existing infrastructure, OpenAI is reaching healthcare users directly, and hospitals are getting better at distinguishing useful products from generic AI wrappers.
Healthcare AI is becoming a bigger market at the same time that simply being a Healthcare AI startup is becoming much less valuable.
If you want more recent data on this point, please see our latest healthcare AI market report.
OUR METHODOLOGY
This analysis tests whether the Healthcare AI market is demonstrably growing now rather than whether market-research firms expect it to become large in the future. We assess growth across capital allocation, hospital deployment, physician adoption, commercial revenue, clinical regulation, consumer usage, competitive dynamics and consolidation.
We prioritize actual behavior over headline market-size forecasts. Funding can rise without adoption, usage can rise without producing viable businesses, and regulatory approvals can grow before commercial demand catches up. The conclusion therefore comes from several independent parts of the market moving in the same direction.
The scope is centered on AI whose economics are directly tied to healthcare delivery: clinical workflows, documentation, healthcare data, imaging, diagnostics, decision support, health information, payer workflows and patient-facing use. Pure AI drug discovery is kept mostly outside the analysis because its timelines and economics are closer to biotechnology.
Freshness matters unusually much in Healthcare AI, so we favor the latest comparable data available and use older figures mainly as baselines. We also separate broad adoption statistics from narrower samples: for example, the Epic ambient-AI hospital study is treated as evidence from a large Epic-based sample, not as a national adoption rate for every U.S. hospital.
Funding is interpreted with concentration in mind. We look not only at total capital raised but also at deal counts, median round sizes and the share of capital absorbed by very large rounds, because current Healthcare AI financing is increasingly concentrated around perceived category leaders.
Commercial evidence is treated similarly. Tempus AI, DeepHealth and OpenEvidence are not added together into a single Healthcare AI revenue estimate because their businesses are different. They are used as separate proof that AI-enabled healthcare products can already generate meaningful revenue across precision medicine, imaging software and physician information.
Regulated clinical AI is assessed separately from workflow AI because the evidence threshold, deployment speed and commercial risk are different. FDA authorizations help show that clinical AI is reaching the market, while physician and hospital adoption data show where lower-risk workflow products are spreading faster.
Key sources used for this analysis include: the American Medical Association's 2026 physician AI survey, JAMA Network Open on generative AI integrated with U.S. hospital EHRs, the American Journal of Managed Care on ambient AI adoption in Epic hospitals, Silicon Valley Bank's healthcare investment analysis, Microsoft on Dragon Copilot adoption, Epic on ambient AI expanding into nursing workflows, Tempus AI's Q2 2026 results, RadNet's Q2 2026 DeepHealth results, KFF's 2026 tracking on AI use for health information, OpenAI on health usage in ChatGPT, FDA material on generative-AI-enabled medical devices, and recent acquisition disclosures from R1, RadNet and Tempus AI.
In our healthcare AI market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Are hospitals actually using AI today?
